BiVictriX Therapeutics PLC
LSE:BVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BiVictriX Therapeutics PLC
Net Issuance of Common Stock
BiVictriX Therapeutics PLC
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BiVictriX Therapeutics PLC
LSE:BVX
|
Net Issuance of Common Stock
£2.1m
|
CAGR 3-Years
128%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Net Issuance of Common Stock
£12.4m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Net Issuance of Common Stock
$140.7m
|
CAGR 3-Years
413%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Net Issuance of Common Stock
£58.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
82%
|
|
|
Niox Group PLC
LSE:NIOX
|
Net Issuance of Common Stock
£100k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-54%
|
CAGR 10-Years
-55%
|
|
BiVictriX Therapeutics PLC
Glance View
BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. The company is headquartered in Alderley Edge, Cheshire and currently employs 5 full-time employees. The company went IPO on 2021-08-11. The firm has developed Bi-Cygni technology, which focuses on an area of unmet medical need. The firm utilizes Bi-Cygni therapeutics, which are designed to selectively target antigen co-expression fingerprints, or twin antigens, on tumour cells, which are absent from healthy cells. The firm has developed Bi-Cygni technology which utilizes Antibody Drug Conjugates, an existing class of potent biological drugs, for the treatment of various cancers including Acute Myeloid Leukaemia. The Company’s Bi-Cygni product candidate, BVX001, which is in early stage development for the treatment of acute myeloid leukaemia (AML). The firm has a diverse panel of cancer-specific twin antigens, across a range of cancer indications that include Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm.
See Also
What is BiVictriX Therapeutics PLC's Net Issuance of Common Stock?
Net Issuance of Common Stock
2.1m
GBP
Based on the financial report for Dec 31, 2023, BiVictriX Therapeutics PLC's Net Issuance of Common Stock amounts to 2.1m GBP.
What is BiVictriX Therapeutics PLC's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
128%
The average annual Net Issuance of Common Stock growth rates for BiVictriX Therapeutics PLC have been 128% over the past three years .
